Discover the latest drugs and treatment options in the Psoriasis Pipeline. Dive into DelveInsight's comprehensive report ...

Women with psoriasis show shorter drug survival for biologics, including IL-17/23 inhibitors, due to lower satisfaction and ...

Discover a study that assessed the risk of hospitalisation for serious infections based on different categories of systemic ...

A new cohort study published in Journal of American Medical Association suggests that biologics targeting IL-12, IL-23, and ...

A growing momentum for earlier treatment of psoriasis has the potential to improve outcomes with oral therapies and biologics ...

The findings highlight the potential benefits of newer biologics targeting IL-12, IL-23, and IL-17 while also raising ...

Department of Medicine, University of Toronto, Women's College Hospital, and co-authors have found biologics targeting ...

BRIDGEWATER, NJ / ACCESS Newswire / March 24, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a ...

In a murine model, a proprietary protease enzyme stabilized platform demonstrated successful delivery of infliximab, a tumor necrosis factor-alpha (TNF-α) inhibitor, in serum with concentrations ...

Infliximab, a TNF-α inhibitor, is a widely used biologic ... psoriatic arthritis, and plaque psoriasis. Globally, infliximab (including biosimilars) generated approximately $6.3 billion in ...

Disease activity was followed with Psoriasis Area and Severity Index ... “many patients with joint pain are put on IL-17 blockers or TNF [tumor necrosis factor] blockers, not only IL-23 blockers ...

Tendering was the most effective policy for reducing expenditures on anti-tumor necrosis factor (TNF) biosimilars in the retail setting, while price links with low discounts were less effective, and ...